Amneal Pharmaceuticals

NSQ:AMRX · US03168L1052

PharmaceuticalsLarge

360

Value57

Profit price65

EV / EBIT78

Price / Owner Earnings52

Cash yield22

Owner Earnings Yield42

Dividend Yield1

Sales & asset price41

Price/Sales80

EV / Gross Profit37

Price/Book7

Quality49

Returns on capital40

Return on Capital71

Cash Return on Capital47

Return on Equity1

Profit margins27

EBIT Margin31

Gross Profitability22

Cash backing63

Cash Conversion90

Accruals75

Owner Earnings Margin25

Growth52

Sales growth27

Profit growth54

Profit Growth83

Long-Term EPS Growth13

Owner Earnings Growth65

Reinvestment82

Price momentum79

Safety21

Debt load9

Debt serviceability47

Refinancing88

Debt Payback5

Liquidity62

Sentiment61

Analyst ratings54

Expectations trend38

Opinion Changes50

Price Target Upside26

Market mood29

Value Creation18/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Amneal Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA

IndustryPharmaceuticals

SizeLarge

TypePublic Company

ExchangeNASDAQGS

Employees4,502

Websiteamneal.com

ISINUS03168L1052

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

OphthalmologyNeurologyRespiratoryOncologyCentral Nervous SystemOsteoporosisEndocrinologyManufacturingMedicalPharmaceutical

Description

Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. The company’s Affordable Medicines segment includes retail generics, injectables, an…

Analysis

Middle-of-the-road

Amneal Pharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is fair. The owner-earnings multiple stands at 22.6×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is stretched. The company scores 18/20 on our value-creation score: strong value creator. Analysts lean positive.

Flags to be aware of: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Amneal Pharmaceuticals with its peers

Karman Holdings

NYQ:KRMN

CountryUSA

IndustryAerospace & Defense

SizeMedium

Full Stock Analysis →

5N Plus

TOR:VNP

CountryCanada

IndustryChemicals

SizeMedium

Full Stock Analysis →

Tarsus Pharmaceuticals

NSQ:TARS

CountryUSA

IndustryPharmaceuticals

SizeMedium

Full Stock Analysis →

Regis

NMQ:RGS

CountryUSA

IndustryDiversified Consumer Services

SizeSmall

Full Stock Analysis →

Moderna

NSQ:MRNA

CountryUSA

IndustryBiotechnology

SizeX-Large

Full Stock Analysis →

Campbell's

NSQ:CPB

CountryUSA

IndustryFood Products

SizeX-Large

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →